SB408: Maryland Department of Health - Reports on Standing Orders and Opioid Overdose Reversal Drugs
Legislative Summary
Requiring the Maryland Department of Health to report, on or before December 1, 2024, December 1, 2025, and December 1, 2026, to the Senate Finance Committee and the House Health and Government Operations Committee on current opioid overdose reversal drugs approved by the federal Food and Drug Administration and, for any approved opioid overdose reversal drug, whether the Department has added the drug to a standing order and, if not, the reasons why the drug has not been added.
Demographic Impact
Overall analysis of equity impact
Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
Amendments
Favorable with Amendments 403529/1 Adopted
Favorable with Amendments 403529/1 Adopted
Roll Call Votes
Status Information
Sponsors
Primary Sponsor
